CA
NZ
UK
AU
IND
US
No company announcement dated October 14, 2026 was found, so the 4.03% gain follows the August 5 second-quarter report rather than a fresh event. Caris Life Sciences reported about 59,200 clinical cases, up about 18%, and more than 114,000 whole exome and whole transcriptome …
No company announcement dated October 14, 2026 was found, so the 3.78% gain follows the August 11 second-quarter report. Zura Bio develops tibulizumab, an antibody aimed at the BAFF and IL-17 pathways, and the program is in two Phase 2 trials. General and administrative …
No company announcement dated October 14, 2026 was found, so the 3.95% gain follows the August 10 second-quarter report. Axsome Therapeutics reported Auvelity net sales of USD 180.3 million, up from USD 119.6 million, plus Sunosi revenue of USD 35.8 million that included USD …
No company announcement dated October 14, 2026 was found, so the 3.35% gain follows the October 8 first-quarter report rather than a new event. AngioDynamics said Auryon atherectomy sales rose 14.7% to USD 18.9 million, NanoKnife irreversible electroporation sales rose 29.0% to USD 8.3 …
● Non-GAAP EPS rose 18% to US$1.62, including US$0.06 from tariff refunds.
● The net loss widened to US$120.4 million from US$82.5 million.
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant recent disclosures. Anteris Technologies Global (NASDAQ:AVR), listed on both Nasdaq and the ASX, is developing the DurAVR transcatheter heart valve and …
Beam Therapeutics (NASDAQ:BEAM) presented initial Phase 1/2 data on October 13 for BEAM-301, an in vivo base editor targeting the R83C variant in glycogen storage disease type Ia, which the company said achieved clinical proof of concept for genetic correction. At baseline, median time …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant recent context. bioAffinity Technologies (NASDAQ:BIAF) is a diagnostics company focused on early lung cancer detection, and it fell 3.17 percent pre-market …
No company release dated October 14 has been located in filings or wire releases reviewed, so this summary relies on the most relevant recent context. Capricor Therapeutics (NASDAQ:CAPR) fell 5.43 percent pre-market to 6.88 dollars on 13,011 shares, and the screener tags the move …
Please wait processing your request...